News

The FDA has granted priority review status to a breast cancer optical imaging agent, Lumisight.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.

Patients with pancreatic and gastric cancers residing in states with expanded Medicaid had improved survival rates.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.

The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.

At the 48th Annual Oncology Nursing Society Congress, nurses shared how they improved travel nurse orientation at their institution.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, highlights how the Oncology Nurse Leader Council at her institution led to frontline nurse task-force engagement.

Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.

The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

The FDA has issued a complete response letter for vic-trastuzumab duocarmazine.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.

Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP, and Rosaleen Bloom, PhD, APRN, ACNS-BC, AOCNS, discuss the financial stressors that face patients undergoing radiation.

Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

A subgroup analysis showed that patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy achieved better outcomes with ribociclib plus letrozole.

Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.

A post-hoc analysis suggests that olaparib may extend progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, no matter their estrogen receptor expression level.

Trastuzumab deruxtecan outperformed investigators choice of therapy, in terms of safety, among patients with HER2-Low Metastatic Breast Cancer.

Using established guidelines to monitor and intervene early for diarrhea and neutropenia may result in longer treatment durations and sustained benefit from sacituzumab govitecan.

Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.

There are many educational resources available for nurses who are interested in improving their spirituality and wellness.

The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.